Skip to main content

Dr. Bhaskar Roy, MBBS

Physical Medicine & Rehabilitation (PM&R) (Neuromuscular Medicine (Psychiatry & Neurology) Physician)

  • Medicare participating

At a glance

Years since graduation
18
In the NPI registry since
2012
Medicare patients seen, 2024
158

Licensed in Connecticut since 2017, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2012Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Neuromuscular Medicine (Psychiatry & Neurology) Physician primary
    CT license 56713 (first issued 2017; active)
  • Behavioral Neurology & Neuropsychiatry Physician
    CT license 56713 (first issued 2017; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Physical Medicine & Rehabilitation (PM&R) per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
158
Services billed
362
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes5015
Established patient office or other outpatient visit, 30-39 minutes4637
Needle measurement of electrical activity in arm or leg muscles, limited study4121
Established patient office or other outpatient visit, 20-29 minutes4031
Needle measurement of electrical activity in arm or leg muscles, complete study1714
Hospital discharge day management, 30 minutes or less1414
New patient office or other outpatient visit, 30-44 minutes1111
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes1111

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Gabapentin
Other prescribers in New Haven, CT
120
Privigen (immun glob g(igg)/pro/iga 0-50)74
Gammagard Liquid (immun glob g(igg)/gly/iga ov50)49
Pregabalin
Other prescribers in New Haven, CT
47
Gamunex-C (immune globul g/gly/iga avg 46)37
Baclofen
Other prescribers in New Haven, CT
23
Hizentra (immun glob g(igg)/pro/iga 0-50)18
Prednisone
Other prescribers in New Haven, CT
18
Mycophenolate Mofetil
Other prescribers in New Haven, CT
12
Neurontin (gabapentin)
Other prescribers in New Haven, CT
11

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 1 payments worth $6,590 in total to this clinician.

By company
Genzyme Corporation$6,590
By type
Consulting Fee$6,590

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
May 30, 2025Genzyme Corporation
May 30, 2025
Consulting Fee$6,590

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Connecticut →

Industry-funded research

Named as a principal investigator on 9 industry-funded studies in 2025, from 5 companies. The companies reported $363,639 in research payments for these studies, mostly to the institutions running them.

  • A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Imm…
    Argenx US, Inc.
  • A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
    Sanofi US Services Inc. · Active, not recruiting · NCT06290128
  • A Study of HyQvia in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in Routine Clinical Care
    Takeda Pharmaceuticals U.S.A., Inc.
  • A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    Sanofi US Services Inc. · Recruiting · NCT06290141
  • A Phase 3, Single-Arm, Multicenter, Open-label Extension of Study ARGX-113-2007 to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Acti…
    Argenx US, Inc.
  • A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Adde…
    AstraZeneca Pharmaceuticals LP
  • A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies (SPIREA)
    Janssen Research & Development, LLC
  • A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants with Primary Immune Thrombocytopenia
    Argenx US, Inc.
  • A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflamm…
    Takeda Pharmaceuticals U.S.A., Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Physical Medicine & Rehabilitation (PM&R) clinicians in New Haven

Sources

NPI registry (CMS NPPES, November 2026; record last updated March 17, 2018), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1629325394. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.